← 返回

NK 细胞免疫代谢作为肝癌治疗的靶点

英文原题:NK cell immunometabolism as target for liver cancer therapy.

查看英文原题

NK cell immunometabolism as target for liver cancer therapy.

PubMed 2022/09/07(内容时间) Int Immunopharmacol Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞正被有效地用作肿瘤免疫治疗中的潜在候选者。然而,NK细胞向实体瘤的迁移和运输是不足的。NK细胞功能障碍、肿瘤侵袭性和转移与肝癌微环境中NK细胞代谢的改变有关。然而,在肝癌中,NK细胞的代谢损伤仍未完全了解。来自各种来源的证据表明,NK细胞的免疫检查点与其代谢检查点的相互作用负责调节这些细胞的发育和功能。免疫检查点如何促进代谢编程仍未完全了解,以及这如何能有益需要更好的理解,但它们正逐渐成为重建肿瘤中NK细胞功能的极其引人注目的方向。它有望代表一个专注于提高基于NK细胞的疗法治疗肝癌疗效的潜在目标。在此,总结了近期在理解肝癌中NK细胞代谢重编程方面取得的进展,以及免疫检查点和代谢检查点在NK细胞功能中可能的相互作用。最后,概述了一些可用于肝癌治疗治疗的潜在代谢相关靶点。

展开英文摘要原文

Natural killer (NK) cells are being used effectively as a potential candidate in tumor immunotherapy.

However, the migration and transport of NK cells to solid tumors is inadequate. NK cell dysfunction, tumor invasiveness, and metastasis are associated with altered metabolism of NK cells in the liver cancer microenvironment.

However, in liver cancers, metabolic impairment of NK cells is still not understood fully. Evidence from various sources has shown that the interaction of NK cell's immune checkpoints with its metabolic checkpoints is responsible for the regulation of the development and function of these cells.

How immune checkpoints contribute to metabolic programming is still not fully understood, and how this can be beneficial needs a better understanding, but they are emerging to be incredibly compelling to rebuilding the function of NK cells in the tumor. It is expected to represent a potential aim that focuses on improving the efficacy of therapies based on NK cells for treating liver cancer.

Here, the recent advancements made to understand the NK cell's metabolic reprogramming in liver cancer have been summarized, along with the possible interplay between the immune and the metabolic checkpoints in NK cell function.

Finally, an overview of some potential metabolic-related targets that can be used for liver cancer therapy treatment has been presented.

论文信息

作者
Wang J、Liu X、Jin T、Cao Y、Tian Y、Xu F
第一作者单位
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.China
通讯作者单位
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: fxu@cmu.edu.cn.China
文献类型
综述
期刊
International immunopharmacology2022 Nov
原文标识
PubMed 36087507 · DOI 10.1016/j.intimp.2022.109193